Thiazides May Up Risk for Skin Cancer in Older Adults
Increased exposure linked to significantly increased rates of incident keratinocyte carcinoma, melanoma in adults ≥66 years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 12, 2021 Category: Cancer & Oncology Tags: Cardiology, Dermatology, Family Medicine, Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news

Thiazides May Up Risk for Skin Cancer in Older Adults
MONDAY, April 12, 2021 -- Higher exposure to thiazides is associated with increased rates of incident keratinocyte carcinoma and melanoma among older adults, according to a study published online April 12 in CMAJ, the journal of the Canadian Medical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 12, 2021 Category: Pharmaceuticals Source Type: news

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for patients with metastatic or locally advanced esophageal or gastroesophageal carcinoma
FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal carcinoma. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA D.I.S.C.O. Burst Edition: FDA approval of Fotivda (tivozanib) for adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies
Listen to a soundcast of the March 10, 2021 FDA approval of Fotivda (tivozanib) for adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Response to Comment on "Tumor-initiating cells establish an IL-33-TGF-{beta} niche signaling loop to promote cancer progression"
Kamphuis et al. argue that macrophages accumulated in the proximity of tumor-initiating cells do not express the high-affinity immunoglobulin E receptor FcRIα. Although we cannot exclude the possibility of nonspecific binding of anti-FcRIα antibody (clone MAR-1), we provide evidence that macrophages in squamous cell carcinomas express FcRIα and that IL-33 induces FcRIα expression in bone marrow cell–derived macrophages. (Source: ScienceNOW)
Source: ScienceNOW - April 8, 2021 Category: Science Authors: Taniguchi, S., Elhance, A., Van Duzer, A., Kumar, S., Leitenberger, J., Oshimori, N. Tags: Immunology, Medicine, Diseases t-comment Source Type: news

Surgical technique may reduce positive margin rate in breast cancer patients with DCIS
(Wake Forest Baptist Medical Center) According to the American Cancer Society, a noninvasive breast cancer called ductal carcinoma in situ (DCIS) accounts for approximately one of every four new breast cancer cases in the United States. If left untreated, DCIS has the potential to evolve into invasive cancer, so many patients choose to have breast-conserving surgery or mastectomy after a diagnosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 5, 2021 Category: Cancer & Oncology Source Type: news

"Rogue" Protein Could Contribute to Humans' High Cancer Rates
A mutant protein called Siglec-XII may promote carcinoma progression in humans, but inactivation of its gene seems to avoid the problem, according to a study. (Source: The Scientist)
Source: The Scientist - April 1, 2021 Category: Science Tags: The Literature Magazine Issue Source Type: news

Obesity Tied to Increased Mortality Overall in Patients With Cancer
Risk for death lower for patients with lung cancer, renal cell carcinoma, melanoma with versus without obesity (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 30, 2021 Category: Cancer & Oncology Tags: Dermatology, Gastroenterology, Gynecology, Internal Medicine, Nephrology, Oncology, Pathology, Pulmonology, Radiology, Journal, Source Type: news

Invasive Lobular Carcinoma: The Importance of This Subtype Invasive Lobular Carcinoma: The Importance of This Subtype
Get up-to-date on the latest research that has advanced our understanding of the pathology and management of this common subtype of breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 30, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Actinic Keratosis Diagnosis Ups Cumulative Risk for Skin Cancer
MONDAY, March 29, 2021 -- The annual increase in risk for cutaneous squamous cell carcinoma (cSCC) is higher for patients who have received a diagnosis of one or more actinic keratoses (AKs), according to a study published online March 24 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 29, 2021 Category: Pharmaceuticals Source Type: news

Monofocal Hepatocellular Carcinoma: How Much Does Size Matter? Monofocal Hepatocellular Carcinoma: How Much Does Size Matter?
This study evaluated the appropriate staging of large monofocal hepatocellular carcinomas. How should tumor size impact treatment?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Deactivating cancer cell gene boosts immunotherapy for head and neck cancers
By targeting an enzyme that plays a key role in head and neck cancer cells, researchers from theUCLA School of Dentistry were able to significantly slow the growth and spread of tumors in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant.Their findings,  published online in the journal Molecular Cell, could help researchers develop more refined approaches to combatting highly invasive head and neck squamous cell cancers, which primarily affect the mouth, nose and throat.Immunotherapy, which is used as a clinical treatment for various cancers, harnesses t...
Source: UCLA Newsroom: Health Sciences - March 23, 2021 Category: Universities & Medical Training Source Type: news

2020 British Guidelines for Cutaneous Squamous Cell Carcinoma 2020 British Guidelines for Cutaneous Squamous Cell Carcinoma
Review a summary of the latest updates regarding clinical management of cutaneous squamous cell carcinoma, as presented in the 2020 guidelines from the British Association of Dermatologists.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 23, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

FDA Approves Merck ’s Keytruda (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) March 23, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 23, 2021 Category: Drugs & Pharmacology Source Type: news

FDA approves pembrolizumab for esophageal or GEJ carcinoma
FDA approved pembrolizumab (Keytruda, Merck Sharp& Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal carcinoma who are not candidates for surgical resection or definitive chemoradiation. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 22, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Sirtex Medical announces new SIR-Spheres(R) DOORwaY-90 Study: The first prospective multicenter U.S.-based trial for registration as first-line treatment for hepatocellular carcinoma
WOBURN, Mass., March 22, 2021 -- (Healthcare Sales & Marketing Network) -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced full FDA approval of the DOORwaY90 Study, a trial evaluating the safety an... Devices, Oncology Sirtex Medical, SIR-Spheres, Y-90 resin microspheres, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news

Oncotarget: Predictors of immunotherapy benefit in Merkel cell carcinoma
(Impact Journals LLC) Dr. Glenn J. Hanna from CCR/NCI in Bethesda, MD as well as The Dana-Farber Cancer Institute in Boston Massachusetts said, " Merkel cell carcinoma (MCC) is a relatively rare cancer, with roughly 400 cases per 100,000 persons each year in the United States " . (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 22, 2021 Category: International Medicine & Public Health Source Type: news

New Barrett's esophagus monitoring method could aid in easier and more precise prognoses
(Case Western Reserve University) Researchers find that a single esophageal brushing, combined with massively parallel sequencing, can identify Barrett's esophagus patients with disease progression to precancerous cells or carcinoma (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 22, 2021 Category: International Medicine & Public Health Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profi...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Boston Scientific Receives FDA Approval for TheraSphere(TM) Y-90 Glass Microspheres
Treatment is the only radioembolization treatment approved for U.S. patients with hepatocellular carcinoma MARLBOROUGH, Mass., March 18, 2021 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) announced it has receiv... Devices, Oncology, FDA Boston Scientific, TheraSphere, Y-90, Glass Microspheres, radioembolization (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 18, 2021 Category: Pharmaceuticals Source Type: news

Oncotarget: Genomic and neoantigen evolution in head and neck squamous cell carcinoma
(Impact Journals LLC) In this Oncotarget study, the authors characterized the mutational and neoantigen burden between primary and first recurrence tumors in 23 patients with HNSCC. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 17, 2021 Category: Cancer & Oncology Source Type: news

More accurate method to predict long term outcomes for pre-invasive breast cancer
(Queen Mary University of London) A study by Queen Mary University of London researchers, funded by Cancer Research UK, confirms the role of the oestrogen receptor biomarker in ductal carcinoma in situ and presents a new and more accurate method to predict long term outcomes for this pre-invasive stage of breast cancer. The study is published in Clinical Cancer Research. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 16, 2021 Category: International Medicine & Public Health Source Type: news

A new type of recyclable: Finding new uses for established drugs
(Tokyo Medical and Dental University) Using cell culture and mouse model approaches, researchers from Tokyo Medical and Dental University (TMDU) have found a novel drug combination that can inhibit tumor growth in oral and esophageal carcinomas. They also identified a potential biomarker that can help predict patient sensitivity to this treatment. These findings provide valuable knowledge for the fight against these deadly cancers and demonstrate a potential new use for drugs currently approved for other diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 16, 2021 Category: Cancer & Oncology Source Type: news

High BMI Tied to Better Overall Survival in Immune Checkpoint Inhibitor-Treated Metastatic RCC High BMI Tied to Better Overall Survival in Immune Checkpoint Inhibitor-Treated Metastatic RCC
In patients with metastatic renal cell carcinoma treated with PD-1/PD-L1-based immune checkpoint inhibitors (ICIs), higher body mass index was associated with improved overall survival in a database study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 15, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FOTIVDA (tivozanib), FDA Approved for Treatment of Relapsed/Refractory Advanced Renal Cell Carcinoma, Available at Biologics by McKesson
CARY, N.C., March 12, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by AVEO Oncology as a specialty pharmacy provider for FOTIVDA® (tivozanib) for the treatment of adult patients with relapsed or refractory advanced renal ... (Source: McKesson News)
Source: McKesson News - March 12, 2021 Category: Information Technology Source Type: news

ASCO, CSCO Outline'Best Practices' for Nasopharyngeal Carcinoma ASCO, CSCO Outline'Best Practices' for Nasopharyngeal Carcinoma
New evidence-based recommendations provide guidance on when to give radiotherapy and chemotherapy to patients with nasopharyngeal carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 11, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Aveo finally earns approval for kidney cancer drug
More than 14 years after Boston-based Aveo Oncology licensed an experimental cancer drug from a Japanese biotech, the company announced Wednesday that the drug has earned approval by the U.S. Food and Drug Administration to treat kidney cancer, ending a long and tumultuous journey. The pill has the generic name of tivozanib, and will be marketed under the brand name, Fotivda, for use by patients with relapsed or refractory advanced renal cell carcinoma who have tried at least two other drugs previously. The… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 10, 2021 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

Aveo finally earns approval for kidney cancer drug
More than 14 years after Boston-based Aveo Oncology licensed an experimental cancer drug from a Japanese biotech, the company announced Wednesday that the drug has earned approval by the U.S. Food and Drug Administration to treat kidney cancer, ending a long and tumultuous journey. The pill has the generic name of tivozanib, and will be marketed under the brand name, Fotivda, for use by patients with relapsed or refractory advanced renal cell carcinoma who have tried at least two other drugs previously. The… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 10, 2021 Category: Biotechnology Authors: Don Seiffert Source Type: news

FDA approves tivozanib for relapsed or refractory advanced renal cell carcinoma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 10, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Fotivda (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma
BOSTON--(BUSINESS WIRE) March 10, 2021 -- AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved Fotivda (tivozanib) for the treatment of adults with relapsed or refractory advanced renal cell... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 10, 2021 Category: Drugs & Pharmacology Source Type: news

Integration analysis of m6A regulators and m6A-related genes in hepatocellular carcinoma
(Compuscript Ltd) Announcing a new article publication forBIO Integration journal. In this article the authors Jingdun Xie, Zhenhua Qi, Xiaolin Luo, Fang Yan, Wei Xing, Weian Zeng, Dongtai Chen and Qiang Li; from Sun Yat-sen University, Guangzhou, Guangdong, China discuss integration analysis of m6A regulators and m6A-related genes in hepatocellular carcinoma (HCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 9, 2021 Category: International Medicine & Public Health Source Type: news

Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer
This study did not meet its primary endpoint of overall survival in the PD-L1 high patient population. Subsequently, the FDA designated the IMvigor130 study as the PMR which will still continue until the final analysis. However, as the treatment landscape in prior-platinum (second-line) mUC has rapidly evolved with the emergence of new treatment options, Roche is voluntarily withdrawing this indication in recognition of the principles of the Accelerated Approval Program.About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called Programmed Death Ligand-1 (PD-L1), which is expressed on tumour c...
Source: Roche Investor Update - March 8, 2021 Category: Pharmaceuticals Source Type: news

Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer
This study did not meet its primary endpoint of overall survival in the PD-L1 high patient population. Subsequently, the FDA designated the IMvigor130 study as the PMR which will still continue until the final analysis. However, as the treatment landscape in prior-platinum (second-line) mUC has rapidly evolved with the emergence of new treatment options, Roche is voluntarily withdrawing this indication in recognition of the principles of the Accelerated Approval Program.About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called Programmed Death Ligand-1 (PD-L1), which is expressed on tumour c...
Source: Roche Media News - March 8, 2021 Category: Pharmaceuticals Source Type: news

New hope for advanced kidney cancer patients
Renal cell carcinoma, the most common form of kidney cancer, can quickly spread through the body and if diagnosed at a late stage it is usually inoperable, with patients given only a year to live. (Source: the Mail online | Health)
Source: the Mail online | Health - March 6, 2021 Category: Consumer Health News Source Type: news

Inovio spinout Geneos closes $12M financing round to advance personalized cancer therapy
The Montgomery County biopharmaceutical company's initial target is a type of liver cancer known as advanced hepatocellular carcinoma. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 4, 2021 Category: Biotechnology Authors: John George Source Type: news

Risk Factors for Development of HCC in Chronic HBV Infection Risk Factors for Development of HCC in Chronic HBV Infection
How do various metabolic factors and comorbidities influence hepatocellular carcinoma risk in patients with chronic hepatitis B infection?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 4, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
WEDNESDAY, March 3, 2021 -- For patients with previously untreated advanced renal cell carcinoma, nivolumab plus cabozantinib has significant benefits over sunitinib with respect to progression-free and overall survival, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 3, 2021 Category: Pharmaceuticals Source Type: news

Enfortumab Vedotin Shows Promise for Urothelial Carcinoma Enfortumab Vedotin Shows Promise for Urothelial Carcinoma
The antibody-drug conjugate enfortumab vedotin is superior to chemotherapy in patients with previously treated advanced urothelial carcinoma, primary results of the EV-301 trial show.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Merck KGaA, Darmstadt, Germany, Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care A Phase II ... Biopharmaceuticals, Oncology, Licensing Merck KGaA, Debiopharm, xevinapant (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 1, 2021 Category: Pharmaceuticals Source Type: news

How Serious Is A Squamous Cell Carcinoma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 1, 2021 Category: General Medicine Source Type: news

Oncotarget: Identification intermediate-risk subgroups in metastatic clear-cell renal cell carcinoma
(Impact Journals LLC) " Elevated PLT count seems to identify a subgroup of patients with poor outcome in the IMDC intermediate-risk population with ccRCC " (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 1, 2021 Category: Cancer & Oncology Source Type: news

Biocon Biologics, Viatris Inc. get CHMP nod for Abevmy, a biosimilar to Avastin
Abevmy is abiosimilar to Roche's Avastin, prescribed for all indications including metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen, it said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 1, 2021 Category: Pharmaceuticals Source Type: news

Cabozantinib may be cost effective in advanced renal cell carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2021 Category: Drugs & Pharmacology Source Type: news

Liver Cancer Profile Differs in Black Patients With Hep C
THURSDAY, Feb. 25, 2021 -- Black patients with hepatitis C virus (HCV) infection develop hepatocellular carcinoma (HCC) at an earlier disease stage and have better liver function at the time of diagnosis, according to a study published online Feb.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 25, 2021 Category: Pharmaceuticals Source Type: news

FDA D.I.S.C.O. Burst Edition: Enhertu (fam-trastuzumab deruxtecan-nxki ) and combination of Opdivo (nivolumab) and Cabometyx (cabozantinib)
Enhertu (fam-trastuzumab deruxtecan-nxki) for locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma and received a prior trastuzumab-based regimen. Combination of Opdivo (nivolumab) + Cabometyx (cabozantinib) as first-line treatment for advanced renal cell carcinoma (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

CT-guided renal ablation is safe for treating cancer in obese patients
CT-guided renal ablation is a safe and effective alternative to nephrectom...Read more on AuntMinnie.comRelated Reading: AI could help radiologists better detect kidney cancer Cryoablation comparable to surgery for kidney cancer Do more CT scans lead to more kidney surgeries? SPECT/CT can solve renal cell carcinoma diagnosis conundrum (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 24, 2021 Category: Radiology Source Type: news

ASCO Announces New Advanced Liver Cancer Guidelines ASCO Announces New Advanced Liver Cancer Guidelines
New guidelines from the American Society of Clinical Oncology were released to address the treatment of advanced hepatocellular carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 24, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Nicotinamide: Safety & Differences From Niacin Nicotinamide: Safety & Differences From Niacin
Nicotinamide, a form of vitamin B3, is an oral treatment option for actinic keratosis, squamous and basal cell carcinomas, and bullous pemphigoid. How does it relate to niacin--and how is it used?Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 23, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news